IP Library Granted Patent US 12,168,037
Granted Patent B2
US 12,168,037 · App. 16/963,421 · Granted Dec 17, 2024

Intracellular IL-1 alpha peptide methods and compositions

Inventors: Jargalsaikhan Dagvadorj (Los Angeles, CA); Moshe Arditi (Encino, CA); Gantsetseg Tumurkhuu (Los Angeles, CA); Janet Markman (Encino, CA)
Assignee: Cedars-Sinai Medical Center
A61K38/2006A61P35/00A61P35/04C07K14/545A61K38/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,037
App. No.
16/963,421
Granted
Dec 17, 2024
Kind
B2
Abstract

Described herein are methods and compositions for the treatment of cancer and cancer metastasis. Methods for the reduction or prevention of cancer metastasis are also described. In particular, the present invention discloses the use of the IL-1α pro-piece peptide in the treatment cancer and cancer metastasis.

Claims (10)

1. A method for reducing and/or reducing the likelihood of cancer metastasis in a subject in need thereof, comprising:

administering a therapeutically effective dosage of a pro-interleukin-1α (pro-IL-1α) peptide mimic to the subject to reduce and/or reduce the likelihood of the cancer metastasis,

wherein the pro-IL-1α peptide mimic consists of the amino acid sequence of SEQ ID NO: 1, or

wherein the pro-IL-1α peptide mimic consists of the amino acid sequence of SEQ ID NO: 1 with 1, 2, or 3 amino acid substitutions, deletions or additions.

2. The method of claim 1 , wherein the pro-IL-1α peptide mimic consists of the amino acid sequence of SEQ ID NO: 1.

3. The method of claim 1 , wherein the pro-IL-1α peptide mimic is formulated in a composition.

4. The method of claim 1 , wherein the metastasis of lung cancer and/or melanoma is reduced.

5. The method of claim 1 , wherein administering the therapeutically effective dosage of the pro-IL-1a peptide mimic reduces AKT serine/threonine kinase 1 (AKT1) activation and glycolysis in the cancer cells.

6. The method of claim 1 , wherein AKT1 phosphorylation in the cancer cells is reduced.

7. The method of claim 1 , wherein the glycolic rate in the cancer cells is decreased.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 25, 2024
From: CEDARS-SINAI MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066373/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2020
From: DAGVADORJ, JARGALSAIKHAN; ARDITI, MOSHE; TUMURKHUU, GANTSETSEG; MARKMAN, JANET
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 053254/0899 →
Continuity (2)
Provisional Application 62621461 · Jan 24, 2018
Related Publication 20210060131A1 · Mar 4, 2021